Multiple Myeloma Coverage from Every Angle

Recent News

Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma
BELLINI Trial of Venetoclax-Based Combination Therapy in Resistant Myeloma
EHA25 Virtual: Long-Term Follow-up of Early Treatment of Smoldering Multiple Myeloma
EHA25 Virtual: Maintenance Myeloma Therapy With Ixazomib and Without AutoSCT
EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma
EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma
ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: BELLINI Trial Update on Venetoclax-Based Regimen in Multiple Myeloma
ASCO20: Long-Term Outcomes With AutoHCT in Multiple Myeloma
ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma
ASCO20: Venetoclax Combination Therapy for Resistant Myeloma
ASCO20: Selinexor-Based Combination Therapy for Resistant Multiple Myeloma
ASCO20: Carfilzomib Versus Bortezomib in Newly Diagnosed Myeloma
Novel Antibody-Drug Conjugate Under Study in Resistant Multiple Myeloma
Biologic Therapies for Patient With Both Multiple Myeloma and Lung Cancer
COVID-19 and Multiple Myeloma: 60-Year-Old Man Successfully Treated With Tocilizumab
Combined Presence of Myeloma and Kidney Cancer: Two Clinical Cases
Using Treatment-Free Interval to Assess Response to Multiple Myeloma Therapy
Daratumumab and Hyaluronidase-fihj Approved by FDA for Multiple Myeloma
Recommendations for Treating Multiple Myeloma During COVID-19 Pandemic
Treating Older Patients With Multiple Myeloma During the COVID-19 Pandemic
Multidrug/Transplant Protocol for High-Risk Smoldering Myeloma
Novel Immunotherapy for Multiple Myeloma: CAR T Cells Targeting CD229
Successful COVID-19 Treatment Reported in a Patient With Multiple Myeloma
Use of Elotuzuzmab, Panobinostat, and Ixazomib in Multiple Myeloma
Which Patients With Myeloma Benefit From Autologous Stem Cell Transplantation?
Myelomatous Pleural Effusion at Time of Initial Diagnosis of Myeloma: Case Report
New Receptor Protein May Successfully Target Multiple Myeloma Cells
Overall Survival With Daratumumab-Based Regimen in Myeloma
Isatuximab-irfc Combination Therapy for Multiple Myeloma Approved by FDA
Study Sheds Light on Genetic Landscape of Resistant Multiple Myeloma
Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma
Phase I Trial Results With Immunotherapy bb21217 for Resistant Multiple Myeloma
Dana-Farber Receives $16.5 Million Gift to Support Multiple Myeloma Research
Combination Therapy for Frail and Unfit Patients Newly Diagnosed With Multiple Myeloma
Belantamab Mafodotin Granted Priority Review by FDA for Resistant Multiple Myeloma
Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
Venetoclax in Combination With Dexamethasone for Resistant Multiple Myeloma
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.